scholarly journals Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study

Cancer ◽  
2007 ◽  
Vol 109 (1) ◽  
pp. 33-40 ◽  
Author(s):  
Heinz-Joseph Lenz ◽  
Fa-Chyi Lee ◽  
Daniel G. Haller ◽  
Deepti Singh ◽  
Al B. Benson ◽  
...  
Keyword(s):  
Gastric Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Efficacy Data ◽  
Safety And Efficacy ◽  
Advanced Gastric Carcinoma ◽  
Multicenter Phase

scholarly journals Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study): A 12-month, randomized, controlled, double-masked, multicenter phase II study

Diabetes Care ◽  
2010 ◽  
Vol 33 (11) ◽  
pp. 2399-2405 ◽  
Author(s):  
P. Massin ◽  
F. Bandello ◽  
J. G. Garweg ◽  
L. L. Hansen ◽  
S. P. Harding ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Safety And Efficacy ◽  
Randomized Controlled ◽  
Multicenter Phase

scholarly journals Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study

2007 ◽  
Vol 96 (7) ◽  
pp. 1043-1046 ◽  
Author(s):  
B Neri ◽  
P Pantaleo ◽  
E Giommoni ◽  
R Grifoni ◽  
C Paoletti ◽  
...  
Keyword(s):  
Gastric Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Line Treatment ◽  
First Line ◽  
Advanced Gastric Carcinoma ◽  
First Line Treatment

scholarly journals Safety and Efficacy of Convalescent Plasma to Treat Severe COVID-19: Protocol for the Saudi Collaborative Multicenter Phase II Study (Preprint)

2020 ◽  
Author(s):  
Mohammed Albalawi ◽  
Syed Ziauddin Ahmed Zaidi ◽  
Nawal AlShehry ◽  
Ahmed AlAskar ◽  
Abdul Rehman Zia Zaidi ◽  
...  
Keyword(s):  
Saudi Arabia ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Collaborative Study ◽  
Rapid Test ◽  
Effective Vaccine ◽  
Control Group ◽  
Inclusion Criteria ◽  
Safety And Efficacy ◽  
Multicenter Phase

BACKGROUND The COVID-19 pandemic is expected to cause significant morbidity and mortality. The development of an effective vaccine will take several months to become available, and its affordability is unpredictable. Transfusion of convalescent plasma (CP) may provide passive immunity. Based on initial data from China, a group of hematologists, infectious disease specialists, and intensivists drafted this protocol in March 2020. OBJECTIVE The aim of this study is to test the feasibility, safety, and efficacy of CP in treating patients with COVID-19 across Saudi Arabia. METHODS Eligible patients with COVID-19 will be recruited for CP infusion according to the inclusion criteria. As COVID-19 has proven to be a moving target as far as its management is concerned, we will use current definitions according to the Ministry of Health (MOH) guidelines for diagnosis, treatment, and recovery. All CP recipients will receive supportive management including all available recommended therapies according to the available MOH guidelines. Eligible CP donors will be patients with COVID-19 who have fully recovered from their disease according to MOH recovery criteria as detailed in the inclusion criteria. CP donors have to qualify as blood donors according to MOH regulations except for the history of COVID-19 in the recent past. We will also test the CP donors for the presence of SARS-CoV-2 antibodies by a rapid test, and aliquots will be archived for future antibody titration. Due to the perceived benefit of CP, randomization was not considered. However, we will compare the outcome of the cohort treated with CP with those who did not receive CP due to a lack of consent or lack of availability. In this national collaborative study, there is a likelihood of not finding exactly matched control group patients. Hence, we plan to perform a propensity score matching of the CP recipients with the comparator group patients for the major characteristics. We plan to collect demographic, clinical, and laboratory characteristics of both groups and compare the outcomes. A total sample size of 575 patients, 115 CP recipients and 460 matched controls (1:4 ratio), will be sufficient to detect a clinically important hospital stay and 30-day mortality difference between the two groups with 80% power and a 5% level of significance. RESULTS At present, patient recruitment is still ongoing, and the interim analysis of the first 40 patients will be shared soon. CONCLUSIONS In this paper, we present a protocol for a national collaborative multicenter phase II study in Saudi Arabia for assessing the feasibility, safety, and potential efficacy of CP in treating patients with severe COVID-19. We plan to publish an interim report of the first 40 CP recipients and their matched comparators soon. CLINICALTRIAL ClinicalTrials.gov NCT04347681; https://clinicaltrials.gov/ct2/show/NCT04347681 INTERNATIONAL REGISTERED REPORT PRR1-10.2196/23543

Extended safety and efficacy data on S-1 plus cisplatin in patients with advanced gastric carcinoma in a multi-center phase II study

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 4083-4083
Author(s):  
H. Lenz ◽  
F. C. Lee ◽  
D. G. Haller ◽  
D. Singh ◽  
A. B. Benson ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Cancer Progression ◽  
Phase Ii ◽  
Phase Iii ◽  
Efficacy Data ◽  
Safety And Efficacy ◽  
Advanced Gastric Carcinoma ◽  
Gastric Cancer Study ◽  
Duration Of Response

4083 Background: We obtained additional phase II safety and efficacy data in a multi-center setting on an active regimen of S-1 plus cisplatin; the experimental arm of the global phase III First-Line Advanced Gastric cancer Study (FLAGS). Methods: Eligible patients had untreated advanced gastric cancer (AGC), histologic proof, KPS ≥70%, adequate organ function, and gave written consent. Patients received S-1 (25mg/m2 p.o. bid on days 1–21) plus cisplatin (75mg/m2 i.v. on day 1) every 28 days. All reported confirmed overall response rate (C-ORR), response durations, and time-to-progression (TTP) are externally reviewed. Results: All 72 patients were assessed for safety and 64 for efficacy. The median age was 56 years and median KPS was 90%. Median no. of cycles was 4. C-ORR was 50% (95% CI, 37%-63%). Median duration of response is >6 months. At 6 months, only 35% of patients have had cancer progression. Median survival (n=72) is 10.5 months (95% CI, 9.3 to NR). At least one SAE occurred in 43% of patients. The frequent grade 3 or 4 adverse events (occurring in >10% of patients) included: fatigue/asthenia (26%), vomiting (21%), nausea (18%), diarrhea (17%), neutropenia (18%), anorexia (11%), and dehydration (11%). Febrile neutropenia (1.4%) and grade 4 diarrhea (1.4%) were rare. Conclusions: These extended data confirm that S-1 plus cisplatin has a very desirable safety profile and impressive efficacy data in AGC. FLAGS will complete accrual of >700 patients by March of 2007. (Supported by Taiho Pharma-USA). [Table: see text]

Weekly etoposide, methotrexate and actinomycin D, alternating with cyclophosphamide plus vincristine (EMA/CO): A phase II study in advanced gastric carcinoma

1991 ◽  
Vol 3 (4) ◽  
pp. 214-216
Author(s):  
P.A. Philip ◽  
G.J. Rustin ◽  
J.A. Ledermann ◽  
R.H.J. Begent ◽  
E.S. Newlands ◽  
...  
Keyword(s):  
Gastric Carcinoma ◽  
Phase Ii ◽  
Actinomycin D ◽  
Phase Ii Study ◽  
Advanced Gastric Carcinoma
Sign in / Sign up

Export Citation Format

Share Document